Program Overview
This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and James R. Klinger, will discuss the overall approach to treatment of pulmonary arterial hypertension (PAH), considering diagnosis, patient characterization, treatment algorithms and patient response. Topics such as the history of pulmonary arterial hypertension, challenges of early diagnosis and risk stratification for patients will be relayed. The expert faculty will also provide a comprehensive update of data regarding current and emerging therapies for the treatment of patients with PAH. At the conclusion of this CME program, learners will better understand best practices for improving outcomes and quality of life for patients with pulmonary arterial hypertension.
Target Audience
Pulmonologists, primary care physicians, PAs, NPs, nurses, pharmacists, and other healthcare professionals involved in the management of patients with PAH
Learning Objectives
- Discuss the most up to date treatment guidelines for the effective care of patients with PAH
- Analyze recent clinical trial data of new therapies for the management of patients with PAH
- Identify treatment goals and develop therapeutic regimens to improve outcomes in patients with PAH
Agenda
- Guideline Update: Recommendations for Effective PAH Patient Care
- A Clinical Data Analysis of New Therapies for the Management of Patients with PAH
- Strategies to Identify Treatment Goals and Personalize Therapeutic Regimens Options
Faculty
Sidney S. Braman, MD
Professor of Medicine
Pulmonary, Critical Care and Sleep Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
James R. Klinger, MD, FCCP
Medical Director, Rhode Island Hospital Pulmonary Hypertension Center
Professor of Medicine
Alpert Medical School of Brown University
Providence, Rhode Island
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Sidney S. Braman, MD
|
Consultant/Advisor: Sunovion Pharmaceuticals Inc.
Speakers Bureau: AstraZeneca Pharmaceuticals; Boehringer Ingelheim; GmbH, Inc; Genentech, Inc. |
| James R. Klinger, MD
|
Consultant/Advisor: Bayer
Grant/Research Support: United Therapeutics |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from Actelion Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Actelion Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
